» Articles » PMID: 33435310

A Narrative Review on Sarcopenia in Type 2 Diabetes Mellitus: Prevalence and Associated Factors

Overview
Journal Nutrients
Date 2021 Jan 13
PMID 33435310
Citations 131
Authors
Affiliations
Soon will be listed here.
Abstract

Type 2 diabetes mellitus (T2DM) represents a major health burden for the elderly population, affecting approximately 25% of people over the age of 65 years. This percentage is expected to increase dramatically in the next decades in relation to the increased longevity of the population observed in recent years. Beyond microvascular and macrovascular complications, sarcopenia has been described as a new diabetes complication in the elderly population. Increasing attention has been paid by researchers and clinicians to this age-related condition-characterized by loss of skeletal muscle mass together with the loss of muscle power and function-in individuals with T2DM; this is due to the heavy impact that sarcopenia may have on physical and psychosocial health of diabetic patients, thus affecting their quality of life. The aim of this narrative review is to provide an update on: (1) the risk of sarcopenia in individuals with T2DM, and (2) its association with relevant features of patients with T2DM such as age, gender, body mass index, disease duration, glycemic control, presence of microvascular or macrovascular complications, nutritional status, and glucose-lowering drugs. From a clinical point of view, it is necessary to improve the ability of physicians and dietitians to recognize early sarcopenia and its risk factors in patients with T2DM in order to make appropriate therapeutic approaches able to prevent and treat this condition.

Citing Articles

Risk factors and an optimized prediction model for urosepsis in diabetic patients with upper urinary tract stones.

Gao C, Liu J, Wang D, Liu M, Qiu J Sci Rep. 2025; 15(1):8183.

PMID: 40065041 PMC: 11893776. DOI: 10.1038/s41598-025-91787-2.


Skeletal muscle atrophy and dysfunction in obesity and type-2 diabetes mellitus: Myocellular mechanisms involved.

Castillo I, Argiles J, Rueda R, Ramirez M, Pedrosa J Rev Endocr Metab Disord. 2025; .

PMID: 40064750 DOI: 10.1007/s11154-025-09954-9.


Sarcopenia and Cardiovascular Diseases in Individuals With Diabetes or Prediabetes.

Wang X, Zeng Q, Yu X, Li S J Clin Hypertens (Greenwich). 2025; 27(3):e70024.

PMID: 40021136 PMC: 11870746. DOI: 10.1111/jch.70024.


Are strategies to increase muscle mass and strength as effective in people with type 2 diabetes?.

Al-Awadi A, Gray S, Al-Ozairi E Rev Endocr Metab Disord. 2025; .

PMID: 39998784 DOI: 10.1007/s11154-025-09947-8.


Personalised screening tool for early detection of sarcopenia in stroke patients: a machine learning-based comparative study.

Yan H, Li J, Li Y, Xian L, Tang H, Zhao X Aging Clin Exp Res. 2025; 37(1):40.

PMID: 39979762 PMC: 11842499. DOI: 10.1007/s40520-025-02945-5.


References
1.
Lee C, Boyko E, Barrett-Connor E, Miljkovic I, Hoffman A, Everson-Rose S . Insulin sensitizers may attenuate lean mass loss in older men with diabetes. Diabetes Care. 2011; 34(11):2381-6. PMC: 3198278. DOI: 10.2337/dc11-1032. View

2.
Wang M, Tan Y, Shi Y, Wang X, Liao Z, Wei P . Diabetes and Sarcopenic Obesity: Pathogenesis, Diagnosis, and Treatments. Front Endocrinol (Lausanne). 2020; 11:568. PMC: 7477770. DOI: 10.3389/fendo.2020.00568. View

3.
Kirkman M, Jones Briscoe V, Clark N, Florez H, Haas L, Halter J . Diabetes in older adults. Diabetes Care. 2012; 35(12):2650-64. PMC: 3507610. DOI: 10.2337/dc12-1801. View

4.
Reijnierse E, Buljan A, Tuttle C, van Ancum J, Verlaan S, Meskers C . Prevalence of sarcopenia in inpatients 70 years and older using different diagnostic criteria. Nurs Open. 2019; 6(2):377-383. PMC: 6419296. DOI: 10.1002/nop2.219. View

5.
Churilov I, Churilov L, MacIsaac R, Ekinci E . Systematic review and meta-analysis of prevalence of sarcopenia in post acute inpatient rehabilitation. Osteoporos Int. 2018; 29(4):805-812. DOI: 10.1007/s00198-018-4381-4. View